163 related articles for article (PubMed ID: 12384813)
1. Investigation of bone disease using isomerized and racemized fragments of type I collagen.
Cloos PA; Fledelius C; Christgau S; Christiansen C; Engsig M; Delmas P; Body JJ; Garnero P
Calcif Tissue Int; 2003 Jan; 72(1):8-17. PubMed ID: 12384813
[TBL] [Abstract][Full Text] [Related]
2. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
[TBL] [Abstract][Full Text] [Related]
3. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
4. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study.
Garnero P; Cloos P; Sornay-Rendu E; Qvist P; Delmas PD
J Bone Miner Res; 2002 May; 17(5):826-33. PubMed ID: 12009013
[TBL] [Abstract][Full Text] [Related]
5. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential.
Cloos PA; Fledelius C
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):473-80. PubMed ID: 10642504
[TBL] [Abstract][Full Text] [Related]
6. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone.
Garnero P; Fledelius C; Gineyts E; Serre CM; Vignot E; Delmas PD
J Bone Miner Res; 1997 Sep; 12(9):1407-15. PubMed ID: 9286756
[TBL] [Abstract][Full Text] [Related]
7. Effect of surgical menopause and Paget's disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: evolution after antiresorptive therapy.
Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Echevarría M; Ros I; Ballesta AM; Muñoz-Gómez J
J Bone Miner Metab; 2002; 20(2):116-20. PubMed ID: 11862534
[TBL] [Abstract][Full Text] [Related]
8. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices.
Woitge HW; Pecherstorfer M; Li Y; Keck AV; Horn E; Ziegler R; Seibel MJ
J Bone Miner Res; 1999 May; 14(5):792-801. PubMed ID: 10320528
[TBL] [Abstract][Full Text] [Related]
9. An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone.
Cloos PA; Lyubimova N; Solberg H; Qvist P; Christiansen C; Byrjalsen I; Christgau S
Clin Lab; 2004; 50(5-6):279-89. PubMed ID: 15209436
[TBL] [Abstract][Full Text] [Related]
10. Markers of bone turnover for the management of patients with bone metastases from prostate cancer.
Garnero P; Buchs N; Zekri J; Rizzoli R; Coleman RE; Delmas PD
Br J Cancer; 2000 Feb; 82(4):858-64. PubMed ID: 10732759
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.
Cloos PA; Christgau S; Lyubimova N; Body JJ; Qvist P; Christiansen C
Breast Cancer Res; 2003; 5(4):R103-9. PubMed ID: 12818000
[TBL] [Abstract][Full Text] [Related]
12. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
Charni N; Juillet F; Garnero P
Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
[TBL] [Abstract][Full Text] [Related]
13. Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations.
Garnero P; Schott AM; Prockop D; Chevrel G
Bone; 2009 Mar; 44(3):461-6. PubMed ID: 19071236
[TBL] [Abstract][Full Text] [Related]
14. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion.
Garnero P; Gineyts E; Arbault P; Christiansen C; Delmas PD
J Bone Miner Res; 1995 Apr; 10(4):641-9. PubMed ID: 7610936
[TBL] [Abstract][Full Text] [Related]
15. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
Garnero P; Gineyts E; Riou JP; Delmas PD
J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
[TBL] [Abstract][Full Text] [Related]
16. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
17. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
18. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
Bonde M; Garnero P; Fledelius C; Qvist P; Delmas PD; Christiansen C
J Bone Miner Res; 1997 Jul; 12(7):1028-34. PubMed ID: 9200001
[TBL] [Abstract][Full Text] [Related]
19. Markers of bone resorption--measurement in serum, plasma or urine?
Huber F; Traber L; Roth HJ; Heckel V; Schmidt-Gayk H
Clin Lab; 2003; 49(5-6):203-7. PubMed ID: 15285175
[TBL] [Abstract][Full Text] [Related]
20. Biochemical assessment of Paget's disease of bone.
Shankar S; Hosking DJ
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P22-7. PubMed ID: 17229003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
